Rosalind
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 2
- OpenAI Acquires AI Drug Research Operations Startup Orchestra Bio
An Edge AI Daily roundup reports that OpenAI announced the acquisition of AI biotechnology operations software company Orchestra Bio on October 20, 2026. Transaction terms were not disclosed. According to the roundup, Orchestra Bio’s team and technology will join OpenAI’s Rosalind life-science model and Rosalind Workbench to support experiment planning and result analysis. The integration plan was not independently corroborated in the supplied material.
钛媒体 · 🔥 0 - OpenAI acquires Orchestra Bio to add drug-development agents to Rosalind
OpenAI said it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and will combine its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. Financial terms were not disclosed; Chinese outlets report Orchestra was founded in San Francisco in 2022 and had raised about $20 million from investors including a16z, 8VC and Insight Partners as of August 2025. OpenAI says Orchestra's agents are designed to track trials and flag affected timelines when something goes wrong, such as a failed production batch, and that Rosalind already counts Moderna and Novo Nordisk as customers. OpenAI frames the deal as a step toward agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.
OpenAI · 🔥 0
Experience and discussion from the community
Share my Rosalind experienceAsk about Rosalind
Nobody has shared their experience with Rosalind yet.